FHC
VKTX icon

First Horizon Corporation’s Viking Therapeutics VKTX Stock Holding History

First Horizon Corporation’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65K Hold
68
– – ﹤0.01% 1323
2026
Q1 		$2.21K Sell
68
-64
-48% -$2.06K ﹤0.01% 1262
2025
Q4 		$4.64K Sell
132
-8
-6% -$283 ﹤0.01% 1225
2025
Q3 		$3.68K Buy
+140
New +$4.18K ﹤0.01% 1229

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

First Horizon Corporation's VKTX Position: Q2 2026 in Review

First Horizon Corporation held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 68 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

First Horizon Corporation first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.64K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • First Horizon Corporation held 68 shares of Viking Therapeutics worth $2.65K as of Q2 2026.
  • First Horizon Corporation left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #1323 holding.
  • First Horizon Corporation first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • First Horizon Corporation's Viking Therapeutics position peaked at $4.64K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.